IRWD Projected Dividend Yield
Com Cl A/Ironwood Pharmaceuticals Inc ( NASDAQ : IRWD )Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing the treatment of GI diseases. Co. is focused on the development and commercialization of GI product opportunities. LINZESS® (linaclotide), Co.'s commercial product, is a product approved by the U.S. Food and Drug Administration in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation. Co. is also developing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis / bladder pain syndrome and endometriosis. 20 YEAR PERFORMANCE RESULTS |
IRWD Dividend History Detail IRWD Dividend News IRWD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |